Paid Ulcerative Colitis Clinical Trials
Ulcerative colitis clinical trials recruiting now. New JAK inhibitors and biologics being studied. Compensation up to $3,500 for qualifying participants.
Compensation
$1,800 - $3,500
Duration
16-52 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-75 years
- Diagnosis of ulcerative colitis for at least 3 months
- Moderate-to-severe active disease (Mayo score 6-12)
- Endoscopic subscore of 2 or higher
- Inadequate response to at least one conventional therapy
- Disease extending at least 15 cm from anal verge
Who May Not Qualify
- Crohn's disease or indeterminate colitis
- Fulminant colitis or toxic megacolon
- Prior colectomy or planned surgery
- CMV colitis
- Current use of IV corticosteroids
Frequently Asked Questions
What medications are being studied for ulcerative colitis?
+
Trials are evaluating new biologics (anti-IL-23, anti-integrin), oral JAK inhibitors, S1P modulators, and novel small molecules. Options exist for patients who are new to biologics or have failed prior treatments.
How often will I need a colonoscopy?
+
Most studies require flexible sigmoidoscopy or colonoscopy at screening and at key timepoints (usually week 8-12 and end of study) to assess mucosal healing.
Can I continue my current UC medications?
+
Oral aminosalicylates are usually permitted at stable doses. Corticosteroids may be allowed initially but are typically tapered. Biologics require a washout period.
What is the main goal of these studies?
+
Studies typically aim to achieve clinical remission (resolution of symptoms) and endoscopic improvement or healing. Many also evaluate quality of life and long-term disease control.